[Form 4] Senti Biosciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Senti Biosciences director Fran Schulz received a stock option grant on June 25, 2025. The grant consists of 21,950 options to purchase common stock at an exercise price of $2.05 per share.

Key terms of the option grant:

• Exercise price: $2.05 per share
• Expiration date: June 24, 2035
• Vesting schedule: 100% vests at earlier of (i) first anniversary of grant date or (ii) 2026 Annual Meeting
• Vesting contingent on continued service through applicable date

The Form 4 was filed by Robert Cutler as attorney-in-fact on June 27, 2025. This transaction represents standard non-employee director equity compensation and aligns the director's interests with shareholders through long-term stock ownership potential.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schulz Fran

(Last) (First) (Middle)

C/O SENTI BIOSCIENCES, INC.

2 CORPORATE DRIVE FIRST FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Senti Biosciences, Inc. [ SNTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.05	06/25/2025		A		21,950		(1)	06/24/2035	Common Stock	21,950	$0	21,950	D

Explanation of Responses:

1. 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2026 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Robert Cutler, attorney-in-fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did SNTI director Fran Schulz receive on June 25, 2025?

Fran Schulz received 21,950 stock options with an exercise price of $2.05 per share. These options were granted on June 25, 2025, and expire on June 24, 2035.

What are the vesting terms for SNTI director Fran Schulz's new stock options?

The stock options vest 100% upon the earlier of (i) the first anniversary of the grant date (June 25, 2026) or (ii) the date of the 2026 Annual Meeting, subject to Schulz's continued service through the applicable vesting date.

How many SNTI shares does Fran Schulz control after the June 25, 2025 option grant?

Following the transaction, Fran Schulz directly owns 21,950 derivative securities (stock options) of SNTI. The Form 4 does not indicate ownership of any non-derivative common stock.

What is the total value of stock options granted to SNTI director Fran Schulz?

Fran Schulz received 21,950 stock options with a strike price of $2.05. The Form 4 indicates the price of the derivative security as $0, as these were granted as director compensation rather than purchased.